Expand the ophthalmology sales force to 125 representatives
Only part of the commitment was delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- 100 of 125 sales representatives
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company plans to expand its sales force to approximately 125 sales representatives in 2021, pending the status of the COVID-19 pandemic.”
What we found
Evidence strength A What the grades mean
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2021.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Rollout
- Indicative materiality
- Low rules
- Action
- Expand
- Deliverable
- sales force of 125 representatives
- Target
- 125 sales representatives
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: pending the status of the COVID-19 pandemic
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Kala Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-KALA-021313 · Corrections policy